???global.info.a_carregar???
Joana Desterro is a PhD/MD currently working as a Clinical Hematologist at Instituto Português de Oncologia, Francisco Gentil of Lisbon. She completed a Chemical Engineering/Biotechnology degree at the Instituto Superior Técnico, University of Lisbon in 1994 and a PhD in Biochemistry in 1999 at the School of Biology, University of St Andrews, UK. In 2012, she was awarded a Medical degree at the Faculty of Medicine, University of Lisbon and completed her Specialist training in Clinical Hematology in 2019. She is an Assistant Professor at the Faculty of Medicine, University of Lisbon and a Researcher at Instituto de Medicina Molecular João Lobo Antunes (Carmo-Fonseca´s Group). Her main motivation in Biomedical Sciences was always related to the regulation of gene expression, namely splicing and SUMO modification, and how errors in these cellular processes lead to cancer development. Her work produced several original research papers.
Read full resume ↓
Identification

Personal identification

Full name
Maria Joana Pinto Desterro

Citation names

  • Desterro, Joana

Author identifiers

Ciência ID
9E11-7F4C-67F4
ORCID iD
0000-0002-6359-7233
Scopus Author Id
6602949583

Email addresses

  • jdesterro@ipolisboa.min-saude.pt (Professional)
  • joanadesterro@gmail.com (Personal)

Addresses

  • Instituto Português de Oncologia de Lisboa Francisco Gentil, Rua Prof Lima Basto, 1099-023, Lisboa, Lisboa, Portugal (Professional)

Knowledge fields

  • Medical and Health Sciences - Clinical Medicine - Hematology
  • Natural sciences - Biological Sciences - Cell Biology
  • Natural sciences - Biological Sciences - Molecular Biology

Languages

Language Speaking Reading Writing Listening Peer-review
English Advanced (C1) Advanced (C1) Advanced (C1) Advanced (C1)
Spanish; Castilian Intermediate (B1) Advanced (C1) Beginner (A1) Intermediate (B1)
French Beginner (A1) Intermediate (B1) Beginner (A1) Beginner (A1)
Education
Degree Classification
2014/01/01 - 2019
Concluded
 Hematologia Clínica (Título de especialista)
Instituto Português de Oncologia de Lisboa Francisco Gentil EPE, Portugal
 19,17
2006 - 2012/06/01
Concluded
 Estudos Básicos de Medicina (Mestrado integrado)
Universidade de Lisboa Faculdade de Medicina, Portugal
"Mestrado Integrado em Medicina" (THESIS/DISSERTATION)
 16
1996 - 1999/10/30
Concluded
 Biochemistry (Doctor of Philosophy)
University of St Andrews, United Kingdom
"Role of SUMO-1 modification in transcriptional activation" (THESIS/DISSERTATION)
 n/a
1989 - 1994/12/01
Concluded
 Engenharia Química - Biotecnologia (Licenciatura)
Universidade de Lisboa Instituto Superior Técnico, Portugal
"n/a" (THESIS/DISSERTATION)
 16
Affiliation

Science

Category
Host institution 		Employer
2004 - Current Researcher (Research) Instituto de Medicina Molecular João Lobo Antunes, Portugal
Instituto de Medicina Molecular João Lobo Antunes, Portugal

Teaching in Higher Education

Category
Host institution 		Employer
2014/01/01 - Current Invited Assistant Professor (University Teacher) Universidade de Lisboa Faculdade de Medicina, Portugal
Universidade de Lisboa Faculdade de Medicina, Portugal
2003/09/30 - 2014/01/01 Assistant Professor (University Teacher) Universidade de Lisboa Faculdade de Medicina, Portugal

Other Careers

Category
Host institution 		Employer
2020 - Current Assistente (Médica) Instituto Português de Oncologia de Lisboa Francisco Gentil EPE, Portugal
Instituto Português de Oncologia de Lisboa Francisco Gentil EPE, Portugal
2014/01/01 - 2019/10/24 Interno (Médica) Instituto Português de Oncologia de Lisboa Francisco Gentil EPE, Portugal
Instituto Português de Oncologia de Lisboa Francisco Gentil EPE, Portugal
2013/01/01 - 2013/12/31 Interno (Médica) Centro Hospitalar Universitário Lisboa Norte EPE, Portugal
Centro Hospitalar Universitário Lisboa Norte EPE, Portugal

Positions / Appointments

Category
Host institution 		Employer
2021/08/01 - Current Coordenadora do Laboratório de Hemato - oncologia Instituto Português de Oncologia de Lisboa Francisco Gentil EPE, Portugal

Others

Category
Host institution 		Employer
2002/09/30 - 2003/09/30 EC Post-Doctoral Fellow Universidade de Lisboa Faculdade de Medicina, Portugal
2000/09/30 - 2002/09/30 EMBO Post-Doctoral Fellow Universidade de Lisboa Faculdade de Medicina, Portugal
1999/10/01 - 2000/09/01 BBRSC Post-Doctoral Fellow University of St Andrews Biomedical Sciences Research Complex, United Kingdom
1996/01/01 - 1999/10/01 Ph.D. Student University of St Andrews, United Kingdom
1995/01/01 - 1995/12/30 Research Technician Instituto Nacional de Saúde Doutor Ricardo Jorge, Portugal
Projects

Grant

Designation Funders
2011/11 - 2014/04 Oncobiology: developing educational tools for a new generation of physician-scientists
Provided by PTCRIS: 116401
 Fundação para a Ciência e a Tecnologia, I.P.
2008/09 - 2008/12 Is microRNA-mediated translational repression involved in auto-regulation of heterodimeric splicing factor U2AF?
ASTF 400-2008
Post-doc Fellow
Friedrich Miescher Institute for Biomedical Research, Switzerland
 European Molecular Biology Laboratory
Concluded
2000/09 - 2002/09 Dynamics of splicing factors
ALTF 239-2000
Post-doc Fellow
Instituto de Medicina Molecular João Lobo Antunes, Portugal
 European Molecular Biology Laboratory
Concluded
1996 - 1999 Role of SUMO modification in Transcription activation
PRAXIS XXI/BD/ 9240 /96
PhD Student Fellow
University of St Andrews Biomedical Sciences Research Complex, United Kingdom
 Fundação para a Ciência e a Tecnologia
Concluded

Contract

Designation Funders
2018/10/01 - 2021/09/30 Diffuse Large B-cell lymphoma blood based proteome signatures
PTDC/BTM-TEC/30087/2017
Researcher
Universidade Nova de Lisboa, Portugal
 Fundação para a Ciência e a Tecnologia
Ongoing
2018/10/01 - 2021/09/30 Targeting Intra-Tumor Heterogeneity as a promising therapeutic strategy for cancer
PTDC/MED-ONC/28660/2017
Researcher
Associação para a Inovação e Desenvolvimento da FCT, Portugal

Instituto de Medicina Molecular João Lobo Antunes, Portugal
Fundação para a Ciência e a Tecnologia
Ongoing
2018/01/01 - 2019/12/31 Characteristics and frequency of IDH mutations and how they associate with other known mutations in myeloid cancer genes in real world AML patients in Portugal
PTDC/MED-FAR/4692/2020
Researcher
Instituto de Medicina Molecular João Lobo Antunes, Portugal
 Celgene Portugal
Concluded
2016/07/01 - 2019/12/31 Novel tumorigenic mechanisms of aberrant epigenetic regulation in clear cell renal cell carcinoma
PTDC/BIM-ONC/0016/2014
Researcher
Instituto de Medicina Molecular João Lobo Antunes, Portugal
 Fundação para a Ciência e a Tecnologia
Concluded
2013/06/01 - 2015/11/30 SETD2 mediates a novel tumor suppressor mechanism that is misregulated in clear cell renal carcinoma
PTDC/BIM-ONC/0384/2012
Researcher
Instituto de Medicina Molecular João Lobo Antunes, Portugal
 Fundação para a Ciência e a Tecnologia
Concluded
2011/11/01 - 2014/04/30 Oncobiology: developing educational tools for a new generation of physician-scientists
HMSP-PCM/0007/2010
Principal investigator
Instituto de Medicina Molecular João Lobo Antunes, Portugal

Centro Hospitalar Universitário Lisboa Norte EPE, Portugal
Fundação para a Ciência e a Tecnologia
Concluded
2011/02/01 - 2014/01/31 Splicing-coupled mechanisms of chromatin remodeling and their global role in transcription
PTDC/BIA-BCM/111451/2009
Researcher
Instituto de Medicina Molecular João Lobo Antunes, Portugal
 Fundação para a Ciência e a Tecnologia
Concluded
2007/01 - 2008/06 Regulation of mRNA processing and transport within the nucleus
Provided by PTCRIS: 82325
Researcher
Fundação para a Ciência e a Tecnologia, I.P.
2007/01 - 2008/03 Expression and Function of Ubiquitin Conjugating Enzyme hsUbc6e
Provided by PTCRIS: 82328
Researcher
Fundação para a Ciência e a Tecnologia, I.P.
2005/07/01 - 2007/06/30 Regulation of mRNA processing and transport within the nucleus
POCI/SAU-MMO/57700/2004
Researcher
Instituto de Medicina Molecular João Lobo Antunes, Portugal
 Fundação para a Ciência e a Tecnologia
Concluded
2005/04/01 - 2007/06/30 Expression and Function of Ubiquitin Conjugating Enzyme hsUbc6e
POCI/SAU-MMO/61129/2004
Researcher
Instituto de Medicina Molecular João Lobo Antunes, Portugal
 Fundação para a Ciência e a Tecnologia
Concluded
Outputs

Publications

Journal article
  1. Filipa Simões; Telma Sequeira; Rita Rosa; Joana Desterro; Maria Almodovar. "Alectinib-induced anemia with acanthocytosis: To proceed or discontinue treatment in Non-Small Cell Lung Cancer patients?". Revista do Grupo de Estudos do Cancro do Pulmão (2023): https://doi.org/10.32932/gecp.2023.12.048.
    10.32932/gecp.2023.12.048
  2. Sónia Matos; Paulo Bernardo; Susana Esteves; Aida Botelho de Sousa; Marcos Lemos; Patrícia Ribeiro; Madalena Silva; et al. "Screening a Targeted Panel of Genes by Next-Generation Sequencing Improves Risk Stratification in Real World Patients with Acute Myeloid Leukemia". Cancers (2022): https://www.mdpi.com/2072-6694/14/13/3236.
    10.3390/cancers14133236
  3. Joana Desterro; Pedro Bak-Gordon; Maria Carmo-Fonseca. "Targeting mRNA processing as an anticancer strategy". Nature Reviews Drug Discovery (2020): https://doi.org/10.1038/s41573-019-0042-3.
    10.1038/s41573-019-0042-3
  4. Oni, Clare; Moonim, Mufaddal; Desterro, Joana; Grattan, Clive; Curto-Garcia, Natalia; Woodley, Claire; Ciesielska, Monika; et al. "UK Single Institution Experience of Mastocytosis: Guy's and St Thomas' NHS Foundation Trust". Blood 134 Supplement (2019): 2960-2960. http://dx.doi.org/10.1182/blood-2019-130477.
    10.1182/blood-2019-130477
  5. Desterro, Joana; McLornan, Donal P.; Curto Garcia, Natalia; O'Sullivan, Jennifer; Alimam, Samah; Keohane, Clodagh; Woodley, Claire; et al. "Essential thrombocythaemia treated with recombinant interferon: ‘real world' United Kingdom referral centre experience". British Journal of Haematology 186 4 (2019): 561-564. http://dx.doi.org/10.1111/bjh.15968.
    10.1111/bjh.15968
  6. Graça, Gonçalo; Desterro, Joana; Sousa, Joana; Fonseca, Carlos; Silveira, Margarida; Serpa, Jacinta; Carvalho, Tânia; da Silva, Maria G.; Gonçalves, Luís G.. "Identification of putative biomarkers for leptomeningeal invasion in B-cell non-Hodgkin lymphoma by NMR metabolomics". Metabolomics 13 11 (2017): http://dx.doi.org/10.1007/s11306-017-1269-9.
    10.1007/s11306-017-1269-9
  7. Delamain MT; da Silva MG; Miranda EC; Desterro J; Luminari S; Fedina A; Merli F; et al. "Age-adjusted international prognostic index is a predictor of survival in gastric diffuse B-cell non-Hodgkin lymphoma patients.". (2016): http://europepmc.org/abstract/med/27521863.
    10.1016/j.bjhh.2016.04.010
  8. Grosso AR; Leite AP; Carvalho S; Matos MR; Martins FB; Vítor AC; Desterro JM; Carmo-Fonseca M; de Almeida SF. "Pervasive transcription read-through promotes aberrant expression of oncogenes and RNA chimeras in renal carcinoma.". (2015): http://europepmc.org/abstract/med/26575290.
    10.7554/elife.09214
  9. Carvalho S; Vítor AC; Sridhara SC; Martins FB; Raposo AC; Desterro JM; Ferreira J; de Almeida SF. "SETD2 is required for DNA double-strand break repair and activation of the p53-mediated checkpoint.". (2014): http://europepmc.org/abstract/med/24843002.
    10.7554/elife.02482
  10. Martins, Ana C.R.; Freitas, Frederico G.; Goncalves, Pedro R.; Prada, Rui; Desterro, Joana M.P.; Costa, L.; Crisostomo, M. Ines. "Developing a prototype of an Oncobiology serious game for medical education". 2013 IEEE 2nd International Conference on Serious Games and Applications for Health (SeGAH) (2013):
    10.1109/segah.2013.6665301
  11. Rino, J.; Desterro, J.M.P.; Pacheco, T.R.; Gadella Jr., T.W.J.; Carmo-Fonseca, M.. "Splicing factors SF1 and U2AF associate in extraspliceosomal complexes". Molecular and Cellular Biology 28 9 (2008): 3045-3057. http://www.scopus.com/inward/record.url?eid=2-s2.0-42349112032&partnerID=MN8TOARS.
    10.1128/MCB.02015-07
  12. Rino, J.; Carvalho, T.; Braga, J.; Desterro, J.M.P.; Lührmann, R.; Carmo-Fonseca, M.. "A stochastic view of spliceosome assembly and recycling in the nucleus". PLoS Computational Biology 3 10 (2007): 2019-2031. http://www.scopus.com/inward/record.url?eid=2-s2.0-35748935227&partnerID=MN8TOARS.
    10.1371/journal.pcbi.0030201
  13. Pacheco, T.R.; Coelho, M.B.; Desterro, J.M.P.; Mollet, I.; Carmo-Fonseca, M.. "In vivo requirement of the small subunit of U2AF for recognition of a weak 3' splice site". Molecular and Cellular Biology 26 21 (2006): 8183-8190. http://www.scopus.com/inward/record.url?eid=2-s2.0-33750053338&partnerID=MN8TOARS.
    10.1128/MCB.00350-06
  14. Boyer-Guittaut, M.; Birsoy, K.; Potel, C.; Elliott, G.; Jaffray, E.; Desterro, J.M.; Hay, R.T.; Oelgeschläger, T.. "SUMO-1 modification of human transcription factor (TF) IID complex subunits: Inhibition of TFIID promoter-binding activity through SUMO-1 modification of hsTAF5". Journal of Biological Chemistry 280 11 (2005): 9937-9945. http://www.scopus.com/inward/record.url?eid=2-s2.0-15444374487&partnerID=MN8TOARS.
    10.1074/jbc.M414149200
  15. Desterro, J.M.P.; Keegan, L.P.; Jaffray, E.; Hay, R.T.; O'Connell, M.A.; Carmo-Fonseca, M.. "SUMO-1 modification alters ADAR1 editing activity". Molecular Biology of the Cell 16 11 (2005): 5115-5126. http://www.scopus.com/inward/record.url?eid=2-s2.0-27644479211&partnerID=MN8TOARS.
    10.1091/mbc.E05-06-0536
  16. Braga, J.; Desterro, J.M.P.; Carmo-Fonseca, M.. "Intracellular macromolecular mobility measured by fluorescence recovery after photobleaching with confocal laser scanning microscopes". Molecular Biology of the Cell 15 10 (2004): 4749-4760. http://www.scopus.com/inward/record.url?eid=2-s2.0-4644243088&partnerID=MN8TOARS.
    10.1091/mbc.E04-06-0496
  17. Desterro, J.M.P.; Keegan, L.P.; Lafarga, M.; Berciano, M.T.; O'Connell, M.; Carmo-Fonseca, M.. "Dynamic association of RNA-editing enzymes with the nucleolus". Journal of Cell Science 116 9 (2003): 1805-1818. http://www.scopus.com/inward/record.url?eid=2-s2.0-0038664237&partnerID=MN8TOARS.
    10.1242/jcs.00371
  18. Xirodimas, D.P.; Chisholm, J.; Desterro, J.M.S; Lane, D.P.; Hay, R.T.. "P14ARF promotes accumulation of SUMO-1 conjugated (H)Mdm2". FEBS Letters 528 1-3 (2002): 207-211. http://www.scopus.com/inward/record.url?eid=2-s2.0-0037174133&partnerID=MN8TOARS.
    10.1016/S0014-5793(02)03310-0
  19. Tatham, M.H.; Jaffray, E.; Vaughan, O.A.; Desterro, J.M.P.; Botting, C.H.; Naismith, J.H.; Hay, R.T.. "Polymeric Chains of SUMO-2 and SUMO-3 are Conjugated to Protein Substrates by SAE1/SAE2 and Ubc9". Journal of Biological Chemistry 276 38 (2001): 35368-35374. http://www.scopus.com/inward/record.url?eid=2-s2.0-0035929557&partnerID=MN8TOARS.
    10.1074/jbc.M104214200
  20. Seeler, J.-S.; Marchio, A.; Losson, R.; Desterro, J.M.P.; Hay, R.T.; Chambon, P.; Dejean, A.. "Common properties of nuclear body protein SP100 and TIF1a chromatin factor: Role of SUMO modification". Molecular and Cellular Biology 21 10 (2001): 3314-3324. http://www.scopus.com/inward/record.url?eid=2-s2.0-0035028618&partnerID=MN8TOARS.
    10.1128/MCB.21.10.3314-3324.2001
  21. Desterro JM; Rodriguez MS; Hay RT. "Regulation of transcription factors by protein degradation.". (2000): http://europepmc.org/abstract/med/11028913.
    10.1007/pl00000760
  22. Midgley CA; Desterro JM; Saville MK; Howard S; Sparks A; Hay RT; Lane DP. "An N-terminal p14ARF peptide blocks Mdm2-dependent ubiquitination in vitro and can activate p53 in vivo.". (2000): http://europepmc.org/abstract/med/10822382.
    10.1038/sj.onc.1203593
  23. Rodriguez, M.S.; Desterro, J.M.P.; Lain, S.; Lane, D.P.; Hay, R.T.. "Multiple C-terminal lysine residues target p53 for ubiquitin-proteasome-mediated degradation". Molecular and Cellular Biology 20 22 (2000): 8458-8467. http://www.scopus.com/inward/record.url?eid=2-s2.0-0033767235&partnerID=MN8TOARS.
    10.1128/MCB.20.22.8458-8467.2000
  24. Hay RT; Vuillard L; Desterro JM; Rodriguez MS. "Control of NF-kappa B transcriptional activation by signal induced proteolysis of I kappa B alpha.". (1999): http://europepmc.org/abstract/med/10582246.
    10.1098/rstb.1999.0504
  25. Duprez E; Saurin AJ; Desterro JM; Lallemand-Breitenbach V; Howe K; Boddy MN; Solomon E; et al. "SUMO-1 modification of the acute promyelocytic leukaemia protein PML: implications for nuclear localisation.". (1999): http://europepmc.org/abstract/med/9885291.
  26. Rodriguez, M.S.; Desterro, J.M.P.; Lain, S.; Midgley, C.A.; Lane, D.P.; Hay, R.T.. "SUMO-1 modification activates the transcriptional response of p53". EMBO Journal 18 22 (1999): 6455-6461. http://www.scopus.com/inward/record.url?eid=2-s2.0-0033571214&partnerID=MN8TOARS.
    10.1093/emboj/18.22.6455
  27. Hay, R.T.; Vuillard, L.; Desterro, J.M.P.; Rodriguez, M.S.. "Control of NF-¿B transcriptional activation by signal induced proteolysis of I¿Ba". Philosophical Transactions of the Royal Society B: Biological Sciences 354 1389 (1999): 1601-1609. http://www.scopus.com/inward/record.url?eid=2-s2.0-0033615293&partnerID=MN8TOARS.
  28. Desterro, J.M.P.; Rodriguez, M.S.; Kemp, G.D.; Ronald T, H.. "Identification of the enzyme required for activation of the small ubiquitin-like protein SUMO-1". Journal of Biological Chemistry 274 15 (1999): 10618-10624. http://www.scopus.com/inward/record.url?eid=2-s2.0-0033537828&partnerID=MN8TOARS.
    10.1074/jbc.274.15.10618
  29. Desterro JM; Rodriguez MS; Hay RT. "SUMO-1 modification of IkappaBalpha inhibits NF-kappaB activation.". (1998): http://europepmc.org/abstract/med/9734360.
    10.1016/s1097-2765(00)80133-1
  30. Giraud, M.-F.; Desterro, J.M.P.; Naismith, J.H.. "Structure of ubiquitin-conjugating enzyme 9 displays significant differences with other ubiquitin-conjugating enzymes which may reflect its specificity for sumo rather than ubiquitin". Acta Crystallographica Section D: Biological Crystallography 54 5 (1998): 891-898. http://www.scopus.com/inward/record.url?eid=2-s2.0-0032168745&partnerID=MN8TOARS.
    10.1107/S0907444998002480
  31. Kroll, Mathias; Conconi, Mariangela; Desterro, Maria Joana P; Marin, Antoine; Thomas, Dominique; Friguet, Bertrand; Hay, Ronald T; et al. "The carboxy-terminus of I¿Ba determines susceptibility to degradation by the catalytic core of the proteasome". Oncogene 15 15 (1997): 1841-1850. http://dx.doi.org/10.1038/sj.onc.1201560.
    10.1038/sj.onc.1201560
  32. Desterro, J.M.P.; Thomson, J.; Hay, R.T.. "Ubch9 conjugates SUMO but not ubiquitin". FEBS Letters 417 3 (1997): 297-300. http://www.scopus.com/inward/record.url?eid=2-s2.0-0030728212&partnerID=MN8TOARS.
    10.1016/S0014-5793(97)01305-7
Thesis / Dissertation
  1. Desterro, Joana. "Role of SUMO modification in transcription activation". PhD, University of St Andrews, 1999.
Activities

Supervision

Thesis Title
Role 		Degree Subject (Type)
Institution / Organization
2017 - 2018 Identification of novel potential therapeutic targets for T-cell acute lymphoblastic leukaemia.
Supervisor
 Estudos Básicos de Medicina (Master)
Universidade de Lisboa Faculdade de Medicina, Portugal

Jury of academic degree

Topic
Role 		Candidate name (Type of degree)
Institution / Organization
2019 Identification of novel potential therapeutic targets for T-cell acute lymphoblastic leukaemia
Supervisor
 Catarina Sofia Micaelo Fernandes (Master)
Universidade de Lisboa Faculdade de Medicina, Portugal
2012 The role of mRNA translation on nonsense-mediated decay inhibition of transcripts carrying a short open reading frame
Thesis Member
 Isabel Cristina Ramos Peixeiro (PhD)
Universidade de Lisboa Faculdade de Ciências, Portugal

Association member

Society Organization name Role
2014 - Current Sociedade Portuguesa de Hematologia Membro
2014 - Current European Haematology Association Member

Conference scientific committee

Conference name Conference host
2018 - 2018 23rd Congress of the European Hematology Association (EHA) Estocolmo, Suécia

Consulting

Activity description Institution / Organization
2017 - Current Participation as co-investigator in Phase II and Phase III Multicenter, Randomized Double Blind, Placebo Controlled Clinical Trials to Evaluate Drugs in the Treatment of Myelodysplastic and Myeloproliferative syndromes; Acute and Chronic Leukemia. Principal Investigator: Francesca Pierdomenico, MD and António Medina de Almeida, MD/PhD. Instituto Português de Oncologia de Lisboa Francisco Gentil EPE, Portugal
2015 - 2016 Technical-scientific consultancy in the pedagogical games component Project “Vivências de Ciência na pré-graduação em Medicina” Programa GAPIC (Gabinete de Apoio à Investigação Científica, Tecnológica e Inovação) PI: Prof. Doutor João Ferreira. Universidade de Lisboa Faculdade de Medicina, Portugal

Course / Discipline taught

Academic session Degree Subject (Type) Institution / Organization
2009 - Current Oncobiology (Tronco Comum V.a) Oncobiologia) Estudos Básicos de Medicina (Licenciatura) Universidade de Lisboa Faculdade de Medicina, Portugal
2007 - Current Molecular Biology of the Cell (Módulo I.I - Biologia Molecular, Celular e do Desenvolvimento Humano e Genética) Estudos Básicos de Medicina (Licenciatura) Universidade de Lisboa Faculdade de Medicina, Portugal
2012 - 2017 Molecular Biology and Gene Expression Oncobiologia (Mestrado integrado) Universidade de Lisboa Faculdade de Medicina, Portugal

Mentoring / Tutoring

Topic Student name
2014 - 2018 Co-transcriptional quality control of mRNA biogeneis: impact for human genetic diseases Rita Catarina Vaz Drago
2011 - 2015 Effects of Chemotherapy and radiotherapy in rectal cancer: significance of different cellular outcomes in tumour behavior Joana Maria Tato Ribeiro da Costa

Other jury / evaluation

Activity description Institution / Organization
2018 - Current Reviewer of abstracts submitted to the 23rd Congress of the European Hematology Association (EHA) “Myelodysplastic syndromes – Biology & Translational Research”
2016 - 2018 Book reviewer for W.W. Norton & Company Ltd. : Case Studies in Cancer. https://www.wwnorton.co.uk/books/9780393679519-case-studies-in-cancer